ESMO Preceptorship on Gastrointestinal Tumours Singapore 2016

Oncology Meeting Resources

20 Oct - 22 Oct, Singapore, Singapore

ESMO Preceptorships Gastric Cancer square

The ESMO Preceptorship on Gastrointestinal Tumours Singapore 2016 was designed for learning about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings; understanding the importance of pathology and histoprognostic factors; learning about the management of patients after progression, side-effects of treatments, and in special situations; learning the fundamental of epidemiology, etiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer; understanding the essentials in the diagnosis and multidisciplinary treatment in gastric cancer and learning about the advances in the treatment and novel targets in gastric cancer.

Presentations of the ESMO Preceptorship on Gastrointestinal Tumours Singapore 2016 are available to ESMO members according to the presenters' agreement to release them. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful links

Presenter Presentation title Session title
D. Aust, DE Microsatellite Instability and Other Molecular Markers - How Useful Are They? SESSION 2 Adjuvant Settings of Colorectal Cancer
C.H. Kohne, DE Adjuvant Treatment for Colon Cancer III SESSION 2 Adjuvant Settings of Colorectal Cancer
F. Seow Choen, SG Adjuvant Treatment of Stage II: Which Patients to Treat? SESSION 2 Adjuvant Settings of Colorectal Cancer
E. Baron, RU 55-year-old Man With Malignant Distal Colonic Obstruction SESSION 2 Adjuvant Settings of Colorectal Cancer
H. Kodrat, ID Low Seated Rectal Cancer SESSION 2 Adjuvant Settings of Colorectal Cancer
A. Sheeraz, PK Ca Rectosigmoid and Duodenal Cancer at the Age of 18 years : Different Histopathology Familial Vs Sporadic SESSION 2 Adjuvant Settings of Colorectal Cancer
C.H. Kohne, DE Development of Conventional Chemotherapy SESSION 3 Metastatic Colorectal Cancer, Liver Limited Metastases
C.H. Kohne, DE Unresectable or Borderline Resectable Chemotherapy +/- Targeted Agents SESSION 3 Metastatic Colorectal Cancer, Liver Limited Metastases
S. Rashad, EG Metastatic Rectal Cancer SESSION 3 Metastatic Colorectal Cancer, Liver Limited Metastases
M.D.A.Bautista, PH Beyond Expectations SESSION 3 Metastatic Colorectal Cancer, Liver Limited Metastases
J.Y. Douillard, CH Options of Locoregional Treatment of Liver Metastasis: Intra-arterial Therapy; Chemo-embolisation; SIRT; Local radiation SESSION 4 Special Clinical Situations: Mono- or Oligometastatic Disease
C. H. Kohne, DE Chemotherapy and Targeted Agents in 1st Line SESSION 5 Metastatic Colorectal Cancer I
J.Y. Douillard, CH The Role of Maintenance, Appropriate Endpoints According to ESMO Consensus SESSION 5 Metastatic Colorectal Cancer I
J.Y. Douillard, CH What to do After 1st Line Failure SESSION 6 Metastatic Colorectal Cancer II
C.H. Kohne, DE Management of Treatment Related Side Effects: GI-Toxicity; Neuropathy; Skin Toxicity; Hypertension; Hand-foot Syndrome SESSION 6 Metastatic Colorectal Cancer II